Compare TUYA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | ANAB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 2015 |
| Metric | TUYA | ANAB |
|---|---|---|
| Price | $2.30 | $55.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.49 | ★ $62.20 |
| AVG Volume (30 Days) | ★ 990.5K | 421.9K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 4.66% | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $91,280,000.00 |
| Revenue This Year | $8.84 | $135.51 |
| Revenue Next Year | $12.17 | N/A |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | N/A | ★ 432.03 |
| 52 Week Low | $1.87 | $14.01 |
| 52 Week High | $4.17 | $57.65 |
| Indicator | TUYA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 64.38 |
| Support Level | $2.24 | $43.67 |
| Resistance Level | $2.45 | $57.65 |
| Average True Range (ATR) | 0.10 | 3.42 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 98.81 | 86.46 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).